The Dell Slim Desktop with Windows 11 for $549.99 is a pretty solid deal if you want a simple home or office computer that ...

The first real-world study of the FDA-approved non-hormone treatment fezolinetant found the menopausal medication improved hot flashes, depression and anxiety in women, according to industry-sponsored ...

See more of our coverage in your search results. Add The New York Post on Google Don’t sweat it. For some, these episodes can be incredibly disruptive to daily life — especially when they happen at ...

Hot flashes affect millions of women during menopause. But what if they’re more than a symptom? Researchers are exploring what they may reveal about women's health, aging, and the body during midlife.

When temperatures climb, so can your chances of having hot flashes. Menopausal symptoms, including both hot flashes and night sweats, tend to show up most frequently in the height of summer — peaking ...

Ever been hit with a sudden wave of heat that leaves you flushed, sweaty and reaching for the nearest fan? Hot flashes are one of the most common—and most disruptive—symptoms of perimenopause and ...

Add Popular Science (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Staying hydrated with cool drinks can reduce the intensity of hot flashes. Spicy foods, caffeine, hot drinks, and alcohol can make hot flashes worse. Hormone replacement therapy may help reduce hot ...

Please provide your email address to receive an email when new articles are posted on . Men with prostate cancer who received 5 mg twice-daily oxybutynin experienced ...

Forbes contributors publish independent expert analyses and insights. Kim Elsesser covers issues that impact women in the workplace. This voice experience is generated by AI. Learn more. This voice ...

A phase 2 randomized, double-blind trial tested oxybutynin 2.5 mg BID and 5 mg BID versus placebo for six weeks in men on stable ADT with ≥28 weekly hot flashes. Dose-dependent efficacy was observed, ...